Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ArcticZymes Technologies ASA (DE:B4V)
FRANKFURT:B4V
RESEARCH TOOLSreports
Holding DE:B4V?
Track your performance easily
B4V Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.06 - €3.74
Previous Close€1.11
Volume0.00
Average Volume (3M)827.00
Market Cap
€58.11M
Enterprise Value€39.00M
Total Cash (Recent Filing)kr238.60M
Total Debt (Recent Filing)kr14.87M
Price to Earnings (P/E)102.4
Beta-0.09
Next Earnings
Jan 30, 2025EPS Estimate
<€0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume827
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)13.23
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ArcticZymes Technologies ASA News
PremiumCompany Announcements
ArcticZymes Innovates Measles Virus Purification Process
PremiumCompany Announcements
ArcticZymes Highlights Growth at SEB Seminar
PremiumCompany Announcements
ArcticZymes Chairman Increases Stake, Boosting Investor Confidence
PremiumCompany Announcements
ArcticZymes Showcases Enzyme Innovations at ESGCT 2024
PremiumCompany Announcements
ArcticZymes Showcases Growth and Innovation at Healthcare Conference
PremiumCompany Announcements
ArcticZymes Innovates Viral Vector Manufacturing
PremiumCompany Announcements
ArcticZymes Unveils Groundbreaking RNA EnzymePremiumCompany Announcements
ArcticZymes Reports Q2 Revenue Dip, Eyes GrowthOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.11% Mutual Funds
― Other Institutional Investors
99.89% Public Companies and
Individual Investors
B4V FAQ
What was ArcticZymes Technologies ASA’s price range in the past 12 months?
ArcticZymes Technologies ASA lowest stock price was €1.06 and its highest was €3.74 in the past 12 months.
What is ArcticZymes Technologies ASA’s market cap?
Currently, no data Available
When is ArcticZymes Technologies ASA’s upcoming earnings report date?
ArcticZymes Technologies ASA’s upcoming earnings report date is Jan 30, 2025 which is in 64 days.
How were ArcticZymes Technologies ASA’s earnings last quarter?
ArcticZymes Technologies ASA released its earnings results on Nov 06, 2024. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of €0.006 by -€0.009.
Is ArcticZymes Technologies ASA overvalued?
According to Wall Street analysts ArcticZymes Technologies ASA’s price is currently Overvalued.
Does ArcticZymes Technologies ASA pay dividends?
ArcticZymes Technologies ASA does not currently pay dividends.
What is ArcticZymes Technologies ASA’s EPS estimate?
ArcticZymes Technologies ASA’s EPS estimate is <€0.01.
How many shares outstanding does ArcticZymes Technologies ASA have?
ArcticZymes Technologies ASA has 51,071,390 shares outstanding.
What happened to ArcticZymes Technologies ASA’s price movement after its last earnings report?
ArcticZymes Technologies ASA reported an EPS of -€0.003 in its last earnings report, missing expectations of €0.006. Following the earnings report the stock price went down -16.058%.
Which hedge fund is a major shareholder of ArcticZymes Technologies ASA?
Currently, no hedge funds are holding shares in DE:B4V
---
ArcticZymes Technologies ASA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
2.02%
Trailing 12-Months
Asset Growth
-2.15%
Trailing 12-Months
Company Description
ArcticZymes Technologies ASA
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments that are Enzymes and Beta-glucans. The company's geographical segments are Norway, Europe, America, Asia/Australia/Africa, out of which Europe accounts for the majority of the revenue.
---
Technical Analysis
---